Kan Chen
Partner at Qiming Venture Partners
About
Kan Chen is a scientist-turned-investor who helped develop Camrelizumab, a cancer drug with >$500M annual sales; he co-leads healthcare, sits on 20+ NASDAQ/Hong Kong/China boards and brokers US–China biotech deals.
Invests in
AI & Machine LearningBiotechConsumerHealthtechSemiconductors
Colleagues at Qiming Venture Partners
Alex Zhou
Managing Partner at Qiming Venture Partners
Alexander Sinclair-Wilson
执行董事 at Qiming Venture Partners
Amy Tang
Venture Partner at Qiming Venture Partners
Biao LU
Associate at Qiming Venture Partners
Bin Liu
Associate at Qiming Venture Partners
Bonnie Wang
Partner at Qiming Venture Partners
Chang Liu
Associate at Qiming Venture Partners
Chris Chen
Investor at Qiming Venture Partners